Phosphodiesterases as Therapeutic Targets for Huntington’s Disease

Author(s): Francesca R. Fusco, Carmela Giampa

Journal Name: Current Pharmaceutical Design

Volume 21 , Issue 3 , 2015

Become EABM
Become Reviewer
Call for Editor


Huntington's disease (HD) is an autosomal-dominant inherited neurodegenerative disorder characterized by motor dysfunction, cognitive decline, and emotional and psychiatric disturbances. The genetic mutation is characterized by a CAG expansion, resulting in the formation of a mutant huntingtin protein with an expanded polyglutamine repeat region. Mutated huntingtin has been shown to impair a number of physiological activities by interacting with several factors. In particular, cAMP response element-binding protein (CREB) and brain-derived neurotrophic factor (BDNF) are severely affected by mutant huntingtin. In this view, drugs targeted at counteracting CREB loss of function and BDNF decrease have been considered as powerful tools to treat HD. Recently, cyclic nucleotide phosphodiesterase (PDE) inhibitors have been used successfully to increase levels of CREB and BDNF in HD models. Indeed, PDE4, 5 or 10 inhibitors have been shown to afford neuroprotection and modulation of CREB and BDNF.

In this review, we will summarize the data supporting the use of PDE inhibitors as the therapeutical approach to fight HD and we will discuss the possible mechanisms of action underlying these effects.

Keywords: Phosphodiesterase inhibitors, cAMP, cGMP, BDNF, CREB, Huntington's disease.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 26 August, 2014
Page: [365 - 377]
Pages: 13
DOI: 10.2174/1381612820666140826113957
Price: $65

Article Metrics

PDF: 45